Further expanding its foot print in the generic drugs market, global drugs behemoth Pfizer is strengthening the collaboration announced earlier this year with Bangalore, India-based Strides Arcolab. It has now signed two licensing and supply agreements which address new markets and product segments.
Under the first agreement, Strides will license and supply up to 38 generic oncology products to Pfizer for markets in the European Union, Canada, Australia, New Zealand, Japan, and Korea. The second agreement covers niche sterile injectables for the US market. The finished dosage form products will be commercialized by Pfizer through its Established Products Business Unit. Financial terms of both agreements were not disclosed.
Pfizer aiming for market leadership in injectables
David Simmons, president and general manager of Pfizer’s Established Products Business Unit, commented: “This continued collaboration also reinforces our commitment to become a leader in the injectables market.”
The new agreements follows that announced in January to deliver 40 generic products, many of which are oncology therapeutics, to health care providers and patients in the USA. With the latest deals, the collaboration between Pfizer and Strides now extends to a total of 45 products addressing countries around the globe. The market size for these 45 products in the USA and other covered geographies is about $18 billion, according to a report by Yahoo India.
Under the new accords, the first of the products is expected to be commercialized in late 2010/early 2011. Pfizer’s Established Products Business Unit launched its US Injectables team about a year ago and it is already marketing products.
NEWS BY INDUSTRY
